Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOLVE: Emetine for COVID-19
NCT05889793Phase 3Terminated
- Sponsor
- Johns Hopkins University
- Start
- May 2024
- Primary completion
- Dec 2025
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of Emetine in coronavirus disease 2019 (COVID-19), sponsored by Johns Hopkins University. Started May 2024; status: terminated.
02
Drugs
Emetine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05889793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05889793.